C-N4KMAptah Bio
RNA therapeutics, transcription modulation, U1 snRNP
repairingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-N4KM
C-N4KMC-N4KMRNA therapeutics, transcription modulation, U1 snRNP
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Aptah Bio RNA therapeutics, transcription modulation, U1 snRNP
Aptah Bio is developing RNA WiCo, described as RNA Widespread Correction, to edit, modulate, and control RNA expression. Its lead compound, APT20TTMG, targets U1-snRNP to extend transcription by preventing premature termination and restoring full-length transcript synthesis. The company says the approach may address cancer, ophthalmology, autoimmune diseases, and neurodegenerative diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Aptah Bio — Early mechanism · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (2 programs at preclinical).…
Source: Deterministic